Abstract 1238P
Background
Identifying driver genes is crucial to make clinical decision for patients with non-small cell lung cancer (NSCLC). Except short turnaround time, higher success rate, it is still debating that PCR may cause false negative result due to its limited coverage. This study directly compared the performance of AmoyDx 11-gene PCR and NGS in the detection of known driver gene mutations in Chinese NSCLC patients.
Methods
FFPE samples from a total of 765 Chinese NSCLC patients were collected. The test performance of AmoyDx 11-gene PCR (EGFR, KRAS, ALK, HER2, ROS1, MET, BRAF, NTRK1/ 2/3, and RET) and NGS were compared.
Results
The overall percent agreement (OPA), positive percent agreement (PPA), and negative percent agreement (NPA) between AmoyDx 11-gene PCR and NGS were 98.8%, 99.3%, and 97.1%, respectively (Table). The PPA between the two assays were the same (100.0%) in common drivers (EGFR/KRAS/ALK) and rare drivers, the OPA and NPA were higher in rare drivers (99.5% vs. 99.9% and 98.8% vs. 99.8%) in AmoyDx 11-gene PCR. For rare drivers, concordance between PCR and NGS were shown in HER2 (OPA: 99.7%, PPA: 95.1% and NPA: 100.0%), ROS1 (OPA: 99.9%, PPA: 100.0% and NPA: 99.9%), MET (OPA:99.9%, PPA:96.4% and NPA:100.0%), BRAF and RET (OPA: 100.0%, PPA: 100.0% and NPA: 100.0%), respectively. Most of interestingly, for EGFR exon 20 insertion (EGFR ex20ins), a good concordance rate of 99.6% (PPA: 100.0% and NPA: 99.6%) was achieved. Table: 1238P
Comparison of AmoyDx 11-gene PCR and NGS for detecting known driver genes in NSCLC patients
NGS (mutant) | NGS (wild) | OPA | PPA | NPA | ||
Total drivers | PCR (mutant) | 591 | 5 | 98.8% | 99.3% | 97.1% |
PCR (wild) | 4 | 165 | ||||
Common drivers | PCR (mutant) | 425 | 4 | 99.5% | 100.0% | 98.8% |
PCR (wild) | 0 | 336 | ||||
Rare drivers | PCR (mutant) | 156 | 1 | 99.9% | 100.0% | 99.8% |
PCR (wild) | 0 | 608 | ||||
EGFR exon20ins | PCR (mutant) | 24 | 3 | 99.6% | 100.0% | 99.6% |
PCR (wild) | 0 | 738 | ||||
HER2 | PCR (mutant) | 39 | 0 | 99.7% | 95.1% | 100.0% |
PCR (wild) | 2 | 724 | ||||
ROS1 | PCR (mutant) | 19 | 1 | 99.9% | 100.0% | 99.9% |
PCR (wild) | 0 | 745 | ||||
BRAF | PCR (mutant) | 19 | 0 | 100.0% | 100.0% | 100.0% |
PCR (wild) | 0 | 746 | ||||
RET | PCR (mutant) | 25 | 0 | 100.0% | 100.0% | 100.0% |
PCR (wild) | 0 | 740 | ||||
MET | PCR (mutant) | 27 | 0 | 99.9% | 96.4% | 100.0% |
PCR (wild) | 1 | 737 |
Conclusions
AmoyDx 11-gene PCR displayed high concordance to NGS in detecting driver mutations of NSCLC, especially rare drivers (EGFR ex20ins), suggesting it is an excellent choice in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Li, F. Gai, C. Zhu: Financial Interests, Personal, Full or part-time Employment: Amoy Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
1251P - Development of a deep learning algorithm for lung cancer diagnosis using methylation and fragment size profiles of cfDNA
Presenter: Jiyoung Huh
Session: Poster session 14
1252P - Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: Presentation of skin tumor data
Presenter: Diederick Keizer
Session: Poster session 14
1253P - Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)
Presenter: Marcel Trautmann
Session: Poster session 14
1254P - Retrospective analysis of brain OMX: Diagnostic tool for structural (T1) and functional connectome (RS-FMRI) analysis of brain
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14
1255P - Evaluating GPT-4 as an academic support tool for clinicians: A comparative analysis of case records from the literature
Presenter: Marcos Aurelio Fonseca Magalhaes Filho
Session: Poster session 14
1256P - Value of detection of peripheral blood circRNA based on digital PCR in the diagnosis of lung adenocarcinoma
Presenter: Jihong Zhou
Session: Poster session 14
1257P - Double heterozygous prevalence in hereditary cancer syndromes in Northern Mexico population
Presenter: Carlos Burciaga Flores
Session: Poster session 14
1258P - Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?
Presenter: Andrea Ciarmiello
Session: Poster session 14
1260TiP - Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach
Presenter: Young-Chul Kim
Session: Poster session 14
1773P - ICECaP-2: Validation of metastasis-free survival (MFS) as a surrogate for overall survival (OS) in localized prostate cancer (LPC) in a more contemporary era
Presenter: Wanling Xie
Session: Poster session 14